Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
NCT03447262 · Vertex Pharmaceuticals Incorporated · PHASE3 · terminated · last registry update 2022-01-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “At Sponsor's Discretion” | – | Registry record, Vertex Pharmaceuticals Incorporated |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CFTR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-01-06Results posted on the registry: Vertex Pharmaceuticals Incorporated, LUM + IVA (NCT03601637)
- 2022-10-24Results posted on the registry: Sandra Swain, Crofelemer (NCT02910219)
- 2022-07-26Results posted on the registry: Vertex Pharmaceuticals Incorporated, ELX/TEZ/IVA + IVA (NCT04353817)
- 2022-07-14Results posted on the registry: Vertex Pharmaceuticals Incorporated, Placebo (matched to VX-121 suspension) + VX-121 (Suspension) (NCT03768089)
- 2022-07-05Phase 3 first posted: Vertex Pharmaceuticals Incorporated, VX-121/TEZ/D-IVA (NCT05444257)
- 2022-06-16Phase 3 first posted: Vertex Pharmaceuticals Incorporated, VX-121/TEZ/D-IVA (NCT05422222)
- 2022-04-15Phase 3 first posted: Vertex Pharmaceuticals Incorporated, ELX/TEZ/IVA + IVA (NCT05331183)
- 2022-03-10Phase 3 first posted: Vertex Pharmaceuticals Incorporated, ELX/TEZ/IVA + IVA (NCT05274269)
- 2022-02-17Also stopped (withdrawn): University of Alabama at Birmingham, Ivacaftor (VX-770) (NCT03251911)
- 2022-01-27Also stopped (withdrawn): University of Alabama at Birmingham, Ivacaftor (NCT04066751)
- 2022-01-25Results posted on the registry: Vertex Pharmaceuticals Incorporated, VX-561 + IVA (NCT03911713)
- 2022-01-18Results posted on the registry: Vertex Pharmaceuticals Incorporated, IVA + TEZ/IVA (NCT03227471)
- 2021-12-16Results posted on the registry: Parion Sciences, VX-371 + Hypertonic Saline (NCT02871778)
- 2021-12-10Phase 3 first posted: Vertex Pharmaceuticals Incorporated, ELX/TEZ/IVA + IVA (NCT05153317)
- 2021-12-08Results posted on the registry: Vertex Pharmaceuticals Incorporated, LUM/IVA + LUM/IVA (NCT03625466)
- 2021-11-26Results posted on the registry: Vertex Pharmaceuticals Incorporated, TEZ/IVA + IVA (NCT03537651)
- 2021-11-08Phase 3 first posted: Vertex Pharmaceuticals Incorporated, ELX/TEZ/IVA + IVA (NCT05111145)
- 2021-10-22Results posted on the registry: Vertex Pharmaceuticals Incorporated, ELX/TEZ/IVA + IVA (NCT03691779)
- 2021-10-13Phase 3 first posted: Vertex Pharmaceuticals Incorporated, VX-121/TEZ/D-IVA + ELX/TEZ/IVA (NCT05076149)
- 2021-09-02Phase 3 first posted: Vertex Pharmaceuticals Incorporated, VX-121/TEZ/D-IVA + ELX/TEZ/IVA (NCT05033080)
- 2021-08-18Results posted on the registry: Vertex Pharmaceuticals Incorporated, ELX/TEZ/IVA + TEZ/IVA (NCT04105972)
- 2021-07-29Results posted on the registry: Parion Sciences, VX-371 + HS + Hypertonic saline (NCT02709109)
- 2021-07-20Phase 3 first posted: Vertex Pharmaceuticals Incorporated, ELX/TEZ/IVA + IVA (NCT04969224)
- 2021-07-02Results posted on the registry: Vertex Pharmaceuticals Incorporated, ELX/TEZ/IVA + IVA (NCT04058353)
- 2021-04-22Results posted on the registry: Vertex Pharmaceuticals Incorporated, VX-659 + TEZ/IVA (NCT03224351)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision